Bavisant
Bavisant has been in phase II clinical trials by Johnson & Johnson for the treatment of attention deficit hyperactivity disorder (ADHD). However, no recent development has been reported.
General Information
Update Date：2015-12-22
- Drug Name：
- Bavisant
- Research Code：
- JNJ-31001074
- Trade Name：
- MOA：
- Histamine H3 receptor antagonist
- Indication：
- Attention deficit hyperactivity disorder (ADHD)
- Status：
- Phase II (Pending)
- Company：
- Johnson & Johnson (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-12-22
|
Molecular Weight | 329.44 | ||||||||||||
| Formula | C19H27N3O2 | |||||||||||||
| CAS No. | 929622-08-2 (Bavisant); | |||||||||||||
| Chemical Name | Methanone, (4-cyclopropyl-1-piperazinyl)[4-(4-morpholinylmethyl)phenyl]- | |||||||||||||
| Bavisant （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||